Announcements
- Predictive Oncology Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors (GPCRs)
- Predictive Oncology Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery
- Predictive Oncology Announces CEO Raymond Vennare to Present at the BIO International Convention 2024
- Predictive Oncology Announces Positive Results from Ovarian Cancer Study with UPMC Magee-Womens Hospital to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Predictive Oncology Reports First Quarter 2024 Financial Results and Provides Business Update
- Predictive Oncology to Report First Quarter 2024 Financial Results on Wednesday, May 15, 2024
- Predictive Oncology Announces Significant Progress with FluGen In the Development of First-of-Its-Kind Intranasal Flu Vaccine
- Predictive Oncology Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Predictive Oncology Reports Year End 2023 Financial Results and Provides Business Update
- Predictive Oncology to Participate in Upcoming Investor Conferences
More ▼
Key statistics
On Friday, Predictive Oncology Inc (S1K:MUN) closed at 1.03, 4.04% above its 52-week low of 0.99, set on Jun 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.03 |
---|---|
High | 1.03 |
Low | 1.03 |
Bid | 0.845 |
Offer | 0.95 |
Previous close | 1.03 |
Average volume | 30.00 |
---|---|
Shares outstanding | 4.10m |
Free float | 3.96m |
P/E (TTM) | -- |
Market cap | 3.97m USD |
EPS (TTM) | -3.66 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 07:08 BST.
More ▼